Not a good buy right now for an impatient investor: price (~34.6) is near resistance (R1 ~34.90 / R2 ~35.26) with limited upside vs Street targets.
Near-term probabilistic pattern scan is bearish (higher odds of declines over 1D/1W/1M).
Options positioning leans defensive (put-heavy open interest), while implied volatility is elevated—typically unfavorable for initiating a straightforward long.
With no near-term catalysts/news and no proprietary buy signals today, the risk/reward skews against buying at current levels.
Momentum: RSI(6)=67.92 (not overbought yet, but close—often where upside starts to get capped).
MACD: Histogram slightly negative (-0.00126) and negatively contracting—momentum is fading rather than accelerating higher.
Levels: Pivot 34.315; support S1 33.731 then S2 33.369. Resistance R1 34.899 then R2 35.261. Current price is closer to resistance than support, which is a poor “must-buy-now” entry.
Sentiment (positioning): Open interest put/call ratio at 1.73 is bearish/hedged (more puts than calls outstanding).
Activity: Option volume is effectively zero today (put/call volume ratio 0.0), so the market isn’t actively expressing fresh bullish conviction via options.
Volatility: 30D IV ~70.98 vs historical vol ~17.08 (very high premium/uncertainty), which often coincides with choppier price action and less attractive long entries.
Technical Summary
Sell
4
Buy
5
Positive Catalysts
was positive (+18.9% YoY).
Neutral/Negative Catalysts
sit below the current price—implying downside/limited upside from Wall Street’s base case.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: 71.161M, +18.90% YoY (top-line growth).
Profitability: Net income -202.111M (still deeply negative; YoY change shown as +300.78% while remaining a large loss). EPS -3.07 (still negative; YoY change shown as +303.95%).
Margin: Gross margin 84.76% (high, but down -15.21% YoY), suggesting deterioration versus last year despite strong reported level.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent rating trend: Neutral/hold-leaning coverage rather than outright bullish.
2025-11-07: RBC Capital reiterated Sector Perform; raised PT to $32 from $28 (incrementally more constructive but still not a Buy).
2025-11-26: Bernstein initiated Market Perform with EUR 27.90 PT, framing GLPG as a “reset”/investment-company model.
Wall Street pros: improving cost/interest structure and strategic reset narrative.
Wall Street cons: targets below spot price and “perform/hold” ratings suggest limited conviction for upside at current levels; more a restructuring/investment story than a clear operating-growth winner right now.
Wall Street analysts forecast GLPG stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLPG is 30.5 USD with a low forecast of 22 USD and a high forecast of 40 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast GLPG stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLPG is 30.5 USD with a low forecast of 22 USD and a high forecast of 40 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
2 Sell
Hold
Current: 33.380
Low
22
Averages
30.5
High
40
Current: 33.380
Low
22
Averages
30.5
High
40
Bernstein
Market Perform
initiated
€27.90
AI Analysis
2025-11-26
Reason
Bernstein
Price Target
€27.90
AI Analysis
2025-11-26
initiated
Market Perform
Reason
Bernstein initiated coverage of Galapagos with a Market Perform rating and EUR 27.90 price target. The firm says the company has transformed itself from a biotech with a cell therapy pipeline into an investment company that seeks to build biotech businesses. Galapagos has undergone a "complete reset," the analyst tells investors in a research note.
RBC Capital
Sector Perform
maintain
$28 -> $32
2025-11-07
Reason
RBC Capital
Price Target
$28 -> $32
2025-11-07
maintain
Sector Perform
Reason
RBC Capital raised the firm's price target on Galapagos (GLPG) to $32 from $28 and keeps a Sector Perform rating on the shares. The firm is citing better than expected cost/interest structure, along with increased Gilead (GILD) amenability to recast Galapagos economics, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GLPG
